Skip to main content

AdaptHealth Corp. (AHCO)

Stock NASDAQ

$7.20

-0.05 (-0.69%)

Delayed quote.

Price history

Daily close
AHCO daily closing price, Nov 24, 2025 to Nov 20, 2026 Closed at $9.86 on Nov 24, 2025 and $7.20 on Nov 20, 2026, a change of -26.98%. Range $5.22 to $13.38.
Daily closes, Nov 24, 2025 to Nov 20, 2026 (250 trading days).
Start
$9.86
Latest close
$7.20
Period change
-26.98%
Period low
$5.22
Period high
$13.38

Key metrics

Market cap
$982.98M
Volume
1.07M
Average volume
2.84M
52-week range
$5.21 – $13.43
Beta
1.32
Last dividend
—
EPS (TTM)
-$2.98
P/E ratio
-19.15
Revenue (TTM)
$3.15B
Net income (TTM)
-$406.73M
Total assets
$4.20B
Total debt
$2.05B
Cash and equivalents
$80.69M

Key financials (trailing twelve months).

Company profile

AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
CEO
Suzanne Foster
Employees
10,900
Headquarters
Conshohocken, PA, US
IPO date
2018-05-31

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$3.24B$3.26B$3.20B
Gross profit$568.56M$681.09M$681.77M
Operating income$186.27M$263.73M-$598.40M
EBITDA$472.53M$628.02M-$171.09M
Net income-$70.79M$90.42M-$678.89M
Diluted EPS-$0.52$0.61-$5.31
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$106.14M$109.75M$77.13M
Total assets$4.32B$4.49B$4.51B
Total liabilities$2.79B$2.91B$3.04B
Total debt$1.90B$2.13B$2.29B
Shareholders’ equity$1.52B$1.57B$1.46B
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$601.77M$541.84M$480.67M
Capital expenditure-$382.39M-$306.06M-$337.46M
Free cash flow$219.38M$235.78M$143.20M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Apr 10, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$745.65M$740.31M$819.80M$846.29M$602.63M$591.81M
Gross profit$114.81M$104.21M$101.40M$162.23M-$55.74M-$53.90M
Operating income-$155.92M-$137.80M$6.89M$54.34M$67.13M$79.25M
EBITDA-$39.02M-$16.18M$111.96M$23.95M$170.94M$156.78M
Net income-$153.99M-$133.93M-$16.04M-$102.77M$24.51M$14.67M
Diluted EPS-$1.13-$0.99-$0.12-$0.73$0.16$0.10
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Apr 10, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$80.69M$43.29M$47.96M$106.14M$80.36M$68.63M
Total assets$4.20B$4.34B$4.42B$4.32B$4.38B$4.35B
Total liabilities$2.97B$2.95B$2.91B$2.79B$2.76B$2.76B
Total debt$2.05B$2.07B$2.00B$1.90B$1.90B$1.95B
Shareholders’ equity$1.23B$1.38B$1.51B$1.52B$1.62B$1.59B
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Apr 10, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$156.59M$145.30M$93.72M$183.18M$161.07M$161.99M
Capital expenditure-$105.53M-$166.24M-$121.21M-$103.90M-$94.24M-$88.67M
Free cash flow$51.06M-$20.94M-$27.49M$79.29M$66.82M$73.33M